Rapid XXXX for detection of anti-factor XIII A subunit antibodies can diagnose 90   % of cases with autoimmune haemorrhaphilia XIII/13.

@entity3459 @entity1 @entity1062 @entity548
UNASSIGNED: Autoimmune haemorrhaphilia XIII/13 (AH13) is an acquired life-threatening @entity3459 due to anti-factor XIII (FXIII) autoantibodies (auto-Abs). AH13 @entity1 may die of @entity548 without correct diagnosis and proper treatment because of lack of awareness and the absence of rapid easy-to-use tests specific for this disease. Currently, the definitive diagnosis is established by cumbersome and time-consuming laboratory tests such as dot-blot assays and enzyme-linked immunosorbent assays (ELISA), and therefore these tests are generally not carried out. To save AH13 @entity1 ' lives, there is an urgent necessity for developing a rapid test for FXIII auto-Abs. We first generated and characterised mouse monoclonal antibodies (mAb) against @entity1 FXIII A subunit (FXIII-A), and then developed a rapid @entity1062 ( @entity1062 ) for detection of anti-FXIII-A auto-Abs using one mAb with a dissociation constant of 9.3 * 10        M. The auto-Ab-FXIII-A complex was captured by the mAb on a nitrocellulose membrane and visualised by Au-conjugated anti-human IgG Ab. Mixing with healthy control plasma improved the detection of auto-Abs in @entity1 having extremely low levels of FXIII-A. The specificity and sensitivity of the @entity1062 were 87   % and 94   %, respectively. We also detected auto-Abs against activated FXIII (FXIIIa) in three @entity1 by pre-converting FXIII to FXIIIa by thrombin treatment. @entity1062 values were significantly inversely correlated with FXIII activity levels, indicating an association between the quantity of anti-FXIII autoantibodies and AH13. This reliable rapid @entity1062 assay can be applied to a point-of-care test to detect anti-FXIII-A auto-Abs, and will contribute to early diagnosis and treatment of AH13.
